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Inhaled disodium cromoglycate (DSCG) as
maintenance therapy in children with asthma:
a systematic review
M J A Tasche, J H J M Uijen, R M D Bernsen, J C de Jongste, J C van der Wouden
Abstract
Background—Disodium cromoglycate
(DSCG) is included in the BTS guidelines
on the treatment of asthma for use in chil-
dren, but is now used only infrequently.
We have identified and interpreted the
findings of all published randomised,
placebo controlled trials of DSCG in the
prophylactic treatment of children with
asthma.
Methods—Several databases were
searched to identify trials. Studies were
included if they investigated subjects with
asthma aged 0–18 years old, addressed
maintenance treatment with inhaled
DSCG, and were published in English.
The methodological quality of the studies
was assessed independently by three re-
viewers. The 95% confidence intervals
(CI) of diVerences in the treatment eVect
for cough and wheeze between placebo
and treatment with DSCG were com-
puted. The estimates were pooled and
tested for homogeneity and, to assess pos-
sible publication bias, a funnel plot was
made and tested for symmetry.
Results—Of the 24 randomised, placebo
controlled trials identified, the method-
ological scores varied widely. The null
hypothesis of homogeneity was rejected.
Under the assumption of heterogeneity
the overall CI for wheeze was 0.11 to 0.26
and for cough was 0.13 to 0.27. The overall
tolerance intervals (–0.11 to 0.48 and –0.04
to 0.43 for wheeze and cough, respectively)
both included zero, so it cannot be
concluded that future studies will show an
eVect of DSCG compared with placebo.
Older studies were more often in favour of
DSCG. The funnel plots suggest publi-
cation bias; small studies with negative or
equal outcomes are lacking.
Conclusion—Given the apparent publi-
cation bias, the small overall treatment
eVect, and the tolerance interval including
zero, there is insuYcient evidence that
DSCG has a beneficial eVect as mainte-
nance treatment in children with asthma.
(Thorax 2000;55:913–920)
Keywords: disodium cromoglycate; asthma; children
Several guidelines for the management of
childhood asthma have been published by
international consensus groups, recommend-
ing early preventive treatment to reduce the
need for bronchodilators and to enable asth-
matic children to lead a normal and active
life.1 2 The consensus statements recommend
disodium cromoglycate (DSCG) as mainte-
nance treatment for children with moderate
asthma. DSCG is supposed to be eVective in
60% of cases,3 but predictors of success are not
known. Although it has been used for decades,
the precise mechanism of its action is still not
fully understood. No serious side eVects have
been reported in trials, but occasional cases of
dysuria, urticaria, bronchospasm, angio-
oedema, and anaphylaxis have been
reported.4–6
In the current review and position statement
of the British Thoracic Society published in
1997 DSCG and inhaled corticosteroids were
both recommended as first choice preventive
treatment in young children rather than DSCG
being recommended as the first choice before
inhaled corticosteroids7; the grounds for this
decision are, however, still unclear. The long
term side eVects of prophylactic treatment with
inhaled steroids in early childhood are un-
known. Nevertheless, there is concern that
treatment of very mild cases of asthma with
inhaled steroids may have an adverse eVect on
the balance between risk and benefit, so DSCG
may still be considered as first choice preven-
tive treatment.7 Other guidelines continue to
recommend DSCG as first choice in young
children.8
The use of DSCG has decreased since 1990
while the use of inhaled corticosteroids is
increasing, even in young children.9 10 Nowa-
days, few consultant paediatricians use DSCG
as first line treatment in young children11 while
some studies suggest overtreatment of children
with mild asthma with inhaled
corticosteroids.9 12
Because of the discrepancy between guide-
lines and daily practice and the debate on the
role of DSCG which led to its withdrawal as
first line treatment in young children, we have
undertaken a systematic review of all published
randomised, placebo controlled trials of
DSCG in the prophylactic treatment of asthma
in children. The aim of the study was to assess
the methodological quality of the studies and
the eVectiveness of inhaled DSCG by statistical
pooling of the study results.
Methods
DATA SOURCES AND STUDY SELECTION
Literature searches of Medline, Embase, the
Cochrane Controlled Trial Register,13 and the
database of the manufacturers of DSCG were
carried out for the period from January 1966 to
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January 1999. The MESH keywords
“asthma”, “sodium cromoglycate”, and “clini-
cal trial” were used to identify relevant articles.
After the search we reviewed the reference lists
of all relevant articles and selected all double
blind, placebo controlled, randomised clinical
trials of maintenance treatment of children
aged 0–18 years published in English.
DATA EXTRACTION
Methodological assessment
All trials were scored according to the criteria
of Chalmers14 and Jadad15 independently by
two of three reviewers (MJAT, JHJMU,
JCvdW), two general practitioners, and a
methodologist. Before scoring the trials the
reviewers mutually adjusted their interpret-
ation of the items. The results were discussed
in a consensus meeting; in cases where there
was a lack of consensus the assessment of the
third reviewer determined the final decision.
To avoid “reviewers’ review bias” our own
trial16 was also scored by an impartial reviewer
(S M A Bierma-Zeinstra).
Description of the studies
The methods and conclusions of the diVerent
trials were summarised and tabulated and the
general outcome of each study was derived
from the conclusions drawn by the authors. A
study was judged positive when the authors
concluded that DSCG was more eVective than
placebo and equal when the authors reported
no diVerence between the treatments.
Statistical pooling
For each study the 95% confidence interval
(CI) for the diVerence in symptom scores
between placebo and DSCG treatment was
calculated separately for wheeze and cough. If
no separate scores were available we used the
score given for daily symptoms. If the pub-
lished data were not suYcient to compute a
95% CI and the trial was published not more
than five years ago, we requested the data from
the authors. If, apart from the statement “not
significant”, no exact p value was given, we cal-
culated the eVect of two extreme alternatives
(p=0.10 and p=0.90). Most studies used a
scale of 0–3; when a diVerent scale was used it
was transformed for our purposes.
DATA SYNTHESIS
We computed the pooled estimates of the
treatment eVect and the pooled 95% CI and
tested the hypothesis of homogeneity.17 In case
of heterogeneity the pooled CI was computed
taking heterogeneity into account.17 We also
computed the corresponding tolerance
interval18 to determine the range of outcomes of
the studies. In order to explain heterogeneity
the influence of study characteristics on the
outcome was evaluated by means of univariate
and multivariate regression analysis (observa-
tions weighted by the reciprocal of the square
of the standard error of the mean diVerence
between placebo and DSCG). The influence of
asthma severity of the study population (ex-
pressed in the mean placebo score) on the out-
come was evaluated by means of functionalTa
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relationships.19 To explore heterogeneity and
publication bias further a funnel plot was con-
structed of the eVect estimate (for wheeze and
cough) against the precision20 for all trials. The
precision of a trial was defined as 1/standard
error. When no exact p value was given (see
above) a p value of 0.10 was assumed. The
symmetry of the funnel plot was tested using a
threshold p value of 0.10.21
To show the relative diVerence in treatment
eVect the relative improvement in mean (RIM
= percentage improvement compared with
placebo) was calculated for each study, as pro-
posed by Calpin et al22:
RIM = (mean score (placebo)—mean score
(DSCG)) × 100/mean score (placebo)
Similar pooling and testing for homogeneity
as described above was performed; for this
procedure a first order approximation was used
as an estimate of the standard error of the RIM.
Results
STUDIES
A total of 251 articles was identified in Medline
of which 18 met our inclusion criteria.23–40
Embase provided one additional trial,16 and
two additional trials were provided by the
database of the pharmaceutical company.41 42
The Cochrane Controlled Trial Register did
not supply further trials but two more trials
were found by searching the references of
relevant articles.43 44 One additional trial45 was
revealed to us by an expert in the field who also
pointed out the trial by Shioda40 which we had
overlooked in the Medline search. Excluded
studies were either not double blind, not
randomised, not controlled, did not concern
the appropriate age group, or investigated the
eVectiveness of DSCG in exercise induced
asthma; one double blind crossover study was
excluded because the results were only partially
presented.46 Thus, 24 randomised controlled
trials of DSCG as a prophylactic agent in chil-
dren with asthma were reviewed (table 1).
Most of the studies were European (n=14, 10
of which were British) or North American
(n=7). Two studies were performed in Israel
and one in Japan. Studies diVered in design,
severity of asthma, number of children in-
cluded, age of children, administration of
medication, and follow up period. In total,
more than 1000 children were studied in the 24
trials with sample sizes ranging from nine to
218; about half of the children (11 trials) were
of preschool age and half were five years or
older (13 trials). Before 1977 the studies
included only children aged four years and
over. The median duration of intervention
(period of active medication in case of cross-
over studies) was 4 weeks (range 3–26). All
studies included children with moderate to
severe asthma, and all but one study were hos-
pital based. In nine papers it was unclear
whether the population was hospitalised or
ambulatory, nor was it clear whether and what
concurrent medication was permitted during
the trial.24 26 31 34 36 38 39 41 45 Only one trial se-
lected children with moderate asthma through
general practitioners.16 Compliance was dis-
cussed in only five papers.16 23 27 28 42
Figure 1 95% confidence intervals of absolute diVerence for (A) cough and (B) wheeze
in DSCG group compared with placebo.
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Figure 2 95% confidence intervals of % improvement for (A) cough and (B) wheeze in
DSCG group compared with placebo.
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SIDE EFFECTS
Fifteen of the trials reported side eVects, all of
which were minor with a low incidence. Cough
was most often reported, followed by bitter
taste, wheezing, sneezing, throat irritation, and
perioral eczema. Some studies did not specify
the kind of adverse eVects but merely stated
“minor”.
OUTCOME
A positive outcome was concluded by the
authors in 16 of the studies and in three the
outcome was partially positive, depending on
age26 and outcome measure.39 45 Five of the
trials had an equal outcome. No studies in
favour of placebo treatment were found.
METHODOLOGICAL ASSESSMENT
The results of the methodological assessments
are given in the last column of table 1.The
Chalmers scores ranged from 24% to 79% with
a mean score of 43% indicating mediocre
methodology. The most prevalent method-
ological shortcomings were in the areas of
compliance, selection and inclusion, and statis-
tics and analysis. The descriptions of blinding
and intervention were relatively good. Four-
teen studies were published before 1980 and
the mean method score for these was similar to
that for the 10 trials reported after 1980. Our
own recent study scored highest; to control for
reviewers’ review bias the independent ob-
server re-evaluated our study which resulted in
similar scores. The Jadad scores ranged from 2
(five studies) to the maximum of 5 (one study).
STATISTICAL POOLING
For most studies the data were insuYcient to
allow a formal meta-analysis with odds ratios.
Two studies did not give symptom score data
or data that could be converted into symptom
scores.32 33 Figure 1 presents two graphs of 95%
CIs of diVerences in mean symptom score
(placebo minus DSCG) for each study. The
CIs are ordered according to year of publi-
cation of the study. In eight studies the CIs
were calculated using the separate symptom
score of wheeze and cough, and in 12 studies
we used daytime symptoms. In two studies36 39
only the results for cough were presented; data
on wheeze were not published because the dif-
ference in treatment eVect between placebo
and DSCG was not significant.
The ÷2 test rejected the hypothesis of homo-
geneity of the study results (p<0.001), both for
the absolute and the relative outcome meas-
ures. Taking heterogeneity into account, the
pooled 95% CIs for wheeze and cough were
0.11 to 0.26 and 0.13 to 0.27, respectively, and
the pooled 95% CIs for RIM were 0.16 to 0.37
and 0.19 to 0.36. The heterogeneity was not
related to the placebo symptom level (that is,
severity of asthma), method of administration
of the medication, duration of follow up,
frequency of dosage, methodological scores,
and other study characteristics. Only year of
publication, age of the children, study design,
and duration of follow up were significant pre-
dictors of outcome in the univariate regression
analysis. The multivariate regression analysis
showed that only year of publication was a sig-
nificant predictor of eVect size: older studies
were more likely to produce a positive eVect of
DSCG treatment. Age of the children, which
was strongly correlated with year of publication
(ñ=0.82), was not significant in this analysis.
The pooled 95% CIs under the assumption of
heterogeneity and the corresponding tolerance
intervals are shown in figs 1 and 2. The latter
include zero, both for the absolute treatment
eVect (–0.11 to 0.48 for wheeze, –0.04 to 0.43
for cough) and for the relative treatment eVect
(–0.12 to 0.64 for wheeze, –0.02 to 0.57 for
cough). The funnel plots are shown in fig 3; the
hypothesis of symmetry was rejected for both
cough (p=0.095) and wheeze (p=0.01). The
asymmetrical funnel plots show that studies
with low precision and negative outcome are
underrepresented, indicating publication bias.
Discussion
Our results show heterogeneity of study results,
a small overall treatment eVect, and publi-
cation bias indicated by the absence of small
negative trials.
STUDY CHARACTERISTICS
Although DSCG was indicated as treatment
for mild to moderate asthma, nearly all trialsFigure 3 Funnel plots for (A) cough (22 studies) and (B) wheeze (20 studies).
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comprised hospital based populations of chil-
dren with moderate to severe asthma. Nine
studies administered the medication with a
nebuliser. Nowadays, spacer devices are avail-
able for young children which are less time
consuming and less tedious to use than
nebulisers, particularly at home. Metered dose
inhalers with spacer devices were used in only
two studies.16 43 Spinhalers were used in 11
trials with older children. The method of
administration, a critical factor in delivery of
drugs to the lungs, was not a predictor of out-
come.
The diagnosis and measurement of asthma
in young children is diYcult47 48 and age eVects
might reduce or mask the eVects of DSCG.
However, this is unlikely since, although
children’s age was a significant predictor for
treatment eVect in the univariate analysis, the
multivariate analysis showed that publication
date of the trial was a confounder for age of the
children. Duration of follow up in most of the
trials did not exceed four weeks which may be
too short to assess the eVect of the treatment.
Although the duration of follow up was not a
predictor of outcome, it was notable that none
of these short term trials had an “equal”
conclusion (12 were positive and two were
positive/equal). In seven studies the authors
tried to find characteristics or criteria to predict
which children would respond to DSCG but
none were found.16 24 25 34 35 37 44 Silverman et al35
reported that only the acute protective eVect of
DSCG in exercise tests predicted the probable
success or failure of long term treatment with
the drug.
EARLIER REVIEWS
The eVects of treatment with DSCG have been
reviewed previously. Edwards49 examined the
evidence for the anti-inflammatory action of
DSCG in adults and children in a large number
of controlled and uncontrolled studies but it is
unclear how these were selected. Hoag and
McFadden50 summarised studies on the eVect
of DSCG on bronchial hyperreactivity in
adults and children. The review by Schweitzer
and Brossier Ballano51 discussed three control-
led studies assessing the eYcacy of DSCG in
children aged two years and younger. Finally,
Holgate52 reviewed recent trials with metered
dose inhalers in children and adults and
discussed challenge studies, therapeutic stud-
ies, and the long term eVects of DSCG. None
of these earlier reviews were systematic,
assessed the methodological quality, or tried to
quantify treatment eVects.
METHODOLOGICAL ASSESSMENT
Meta-analyses have been criticised but they are
becoming increasingly popular because they
give insight into the combined results of trials
and provide data for rational decision
making.53 54 A review of scales and checklists for
assessing the quality of randomised controlled
trials shows limitations in virtually every
scale.55 We decided to use the items proposed
by Chalmers15 because these address both the
methodology and the presentation of the study
extensively. However, we found shortcomings
while using the scale, including the lack of
attention to sample size, protocol violations,
and permitted concurrent medication. The
methodological quality of the trials was medio-
cre, as shown by the mean score of 43% of the
maximum attainable. We have to take into
account the fact that 13 studies were published
before 1980. Informed consent, clear descrip-
tion of inclusion criteria, rejection logs and
baseline characteristics, adequate sample size
calculation, calculation of confidence intervals,
and regression analysis were not common
practice at that time.
We also scored the trials according to the
criteria of Jadad as this is the only validated
scoring system available.15 This scoring system
was not found to be very discriminatory
because, when dealing with randomised, pla-
cebo controlled trials only, as in our review, the
outcome score was limited to 2–5. However,
half of the studies scored 3 points or less, which
is compatible with serious or extensive flaws.
STATISTICAL POOLING
The estimates of the diVerences between
placebo and DSCG treatment for cough and
wheeze symptom scores (assuming heterogen-
eity) were 0.17 and 0.11, respectively, which
suggests a small therapeutic eVect for DSCG.
We doubt whether an eVect of this size is of
clinical relevance. On the other hand, the over-
all relative improvement estimates were 27%
and 26%, respectively. This considerable rela-
tive improvement combined with the minor
absolute improvement shows that, overall, the
severity of symptoms under placebo treatment
was low. Indeed, although most studies in our
review included children with severe asthma,
the mean daily symptom score in the placebo
groups was low (0.8), probably because of
dilution by symptom free days which is a com-
mon finding in trials of childhood asthma.56 57
Care must be taken in drawing definitive
conclusions about the role of DSCG in the
treatment of asthma in children on the basis of
this review for several reasons. Medical litera-
ture can be misleading as a result of selective
submission and publication of randomised
controlled trials showing a statistically signifi-
cant treatment eVect.58 The year of publication
of the study proved to be the most significant
predictor of treatment eVect and the asym-
metrical shape of the funnel plots suggests bias;
studies with a positive treatment eVect had
relatively little precision and most were per-
formed before 1980. Trials with little precision
and a negative outcome have probably not been
submitted or published, which is understand-
able in a period when a newly developed drug
is tested and marketed. Our meta-analysis is
therefore optimistic in its outcome; the addi-
tion of unpublished negative trials would
change the results towards an even more nega-
tive conclusion.
The trials were heterogeneous in their treat-
ment eVects. Refraining from pooling was seri-
ously considered, given the heterogeneity and
the suspected publication bias. Nevertheless,
we calculated the pooled confidence intervals
and the tolerance intervals because these are
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useful summary measures. In cases of
heterogeneity, in particular, we consider the
tolerance interval to be more informative than
the (heterogeneous) confidence interval be-
cause the first gives the range of treatment
eVects found by studies while the latter is a
confidence interval for a theoretical treatment
eVect.
In two trials36 39 the results for wheeze were
not published because the diVerence between
placebo and DSCG was not significant. This
could result in some bias in favour of DSCG in
the calculation for wheeze. On the other hand,
two trials32 33 with a positive outcome were
omitted from the pooling because the pub-
lished data were insuYcient. The results of the
statistical pooling were based on symptoms
only because symptom scores were available in
all trials.
We did not include studies on the immediate
eVects of DSCG on exercise induced asthma.
This is a diVerent issue which does not pertain
to the use of DSCG as advised in the current
guidelines. Finally, we did not include studies
on the eVects of combined treatment—that is,
the corticosteroid sparing eVects of DSCG.
Given the strong indication of publication
bias, the tolerance interval including zero, and
the small overall treatment eVect, we conclude
that, on the basis of published randomised
trials, the superiority of DSCG over placebo in
the maintenance treatment of children with
asthma is not proven. We therefore consider
that it is no longer justified to recommend
DSCG as a first line prophylactic agent in
childhood asthma.
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